I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| hepatocyte | 5 studies | 53% ± 21% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| hepatocyte | 5 studies | 53% ± 21% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| liver | 3 studies | 38% ± 21% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| liver | 100% | 34408.54 | 226 / 226 | 99% | 1741.22 | 403 / 406 |
| brain | 99% | 168.32 | 2618 / 2642 | 81% | 4.29 | 574 / 705 |
| pancreas | 74% | 21.06 | 243 / 328 | 74% | 6.48 | 131 / 178 |
| lung | 73% | 24.83 | 420 / 578 | 25% | 3.87 | 294 / 1155 |
| kidney | 82% | 42.85 | 73 / 89 | 11% | 1.47 | 102 / 901 |
| spleen | 93% | 94.67 | 224 / 241 | 0% | 0 | 0 / 0 |
| adrenal gland | 81% | 69.76 | 210 / 258 | 7% | 0.22 | 15 / 230 |
| uterus | 72% | 18.88 | 123 / 170 | 12% | 0.93 | 53 / 459 |
| bladder | 67% | 16.86 | 14 / 21 | 13% | 0.63 | 68 / 504 |
| intestine | 67% | 16.51 | 650 / 966 | 11% | 2.87 | 59 / 527 |
| stomach | 58% | 14.14 | 207 / 359 | 17% | 3.02 | 50 / 286 |
| prostate | 69% | 16.33 | 168 / 245 | 4% | 0.07 | 18 / 502 |
| blood vessel | 72% | 19.32 | 961 / 1335 | 0% | 0 | 0 / 0 |
| muscle | 69% | 16.19 | 558 / 803 | 0% | 0 | 0 / 0 |
| thymus | 61% | 13.77 | 400 / 653 | 5% | 0.07 | 28 / 605 |
| breast | 47% | 18.58 | 214 / 459 | 15% | 1.40 | 167 / 1118 |
| esophagus | 47% | 10.81 | 684 / 1445 | 11% | 5.87 | 21 / 183 |
| ovary | 41% | 8.46 | 74 / 180 | 17% | 2.28 | 75 / 430 |
| peripheral blood | 49% | 42.13 | 452 / 929 | 0% | 0 | 0 / 0 |
| skin | 30% | 6.59 | 547 / 1809 | 7% | 0.35 | 33 / 472 |
| adipose | 25% | 9.91 | 307 / 1204 | 0% | 0 | 0 / 0 |
| heart | 19% | 5.03 | 162 / 861 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 2% | 0.04 | 1 / 45 |
| eye | 0% | 0 | 0 / 0 | 1% | 0.02 | 1 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0030212 | Biological process | hyaluronan metabolic process |
| GO_0072562 | Cellular component | blood microparticle |
| GO_0005788 | Cellular component | endoplasmic reticulum lumen |
| GO_0070062 | Cellular component | extracellular exosome |
| GO_0005576 | Cellular component | extracellular region |
| GO_0062023 | Cellular component | collagen-containing extracellular matrix |
| GO_0004866 | Molecular function | endopeptidase inhibitor activity |
| GO_0004867 | Molecular function | serine-type endopeptidase inhibitor activity |
| GO_0005540 | Molecular function | hyaluronic acid binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | ITIH2 |
| Protein name | Inter-alpha (Globulin) inhibitor H2 (cDNA FLJ75038, highly similar to Homo sapiens inter-alpha (globulin) inhibitor H2 (ITIH2), mRNA) Inter-alpha-trypsin inhibitor heavy chain 2 Inter-alpha-trypsin inhibitor heavy chain H2 (ITI heavy chain H2) (ITI-HC2) (Inter-alpha-inhibitor heavy chain 2) (Inter-alpha-trypsin inhibitor complex component II) (Serum-derived hyaluronan-associated protein) (SHAP) |
| Synonyms | hCG_25115 IGHEP2 |
| Description | FUNCTION: May act as a carrier of hyaluronan in serum or as a binding protein between hyaluronan and other matrix protein, including those on cell surfaces in tissues to regulate the localization, synthesis and degradation of hyaluronan which are essential to cells undergoing biological processes. |
| Accessions | ENST00000429820.5 A2RTY6 ENST00000358415.9 ENST00000379587.4 P19823 Q5T985 Q5T987 |
